Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Verseon Corporation LSE:VERS London Ordinary Share COM USD0.001 (DI)
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 50.50p 50.00p 51.00p 50.50p 49.30p 49.30p 0 08:00:29
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -15.1 -9.6 - 80.56

Verseon Corporation Update to Admission of Subscription Shares

22/03/2019 7:01am

UK Regulatory (RNS & others)


Verseon (LSE:VERS)
Historical Stock Chart

3 Months : From Feb 2019 to May 2019

Click Here for more Verseon Charts.

TIDMVERS

RNS Number : 6595T

Verseon Corporation

22 March 2019

March 22, 2019

Verseon Corporation

("Verseon" or the "Company")

Update to Admission of Subscription Shares

FREMONT, Calif.-Verseon, a clinical-stage pharmaceutical company developing disruptive life-science technologies to advance global health, today announces that further to the announcement on March 19, 2019, the Directors now expect that Admission of the Subscription Shares will take place at 8:00 a.m. on Thursday, March 28, 2019.

About Verseon

Verseon Corporation (AIM:VERS) is developing disruptive life-science technology to advance global health. The clinical-stage company is using its proprietary, computational drug discovery platform to discover new drug candidates that are unlikely to be found using conventional methods. Pairing its computational engines with a comprehensive in-house chemistry and biology workflow, the company has built a growing pipeline of drug programs. Verseon currently has four active drug programs in the areas of anticoagulation, diabetic macular edema, hereditary angioedema, and oncology.

Find Verseon on Twitter and LinkedIn.

- Ends -

For further information, please contact:

 
 Verseon Corporation                        www.verseon.com 
 Sebastian Wykeham / Tina Schlafly          +1 (510) 225 9000 
 
 Arden Partners (NOMAD and Joint Broker) 
 Ruari McGirr / Ciaran Walsh / Alex          +44 (0) 20 7614 
  Penney                                      5900 
 
 Cantor Fitzgerald Europe (Joint Broker) 
                                            +44 (0) 20 7894 
 Phil Davies                                 7000 
 

For financial and business media enquiries, please contact

 
 Buchanan Communications Ltd (PR Advisers) 
                                              +44 (0) 20 7466 
 Henry Harrison-Topham / Jamie Hooper          5000 
 

For trade and pharma media enquiries, please contact

 
 Vane Percy & Roberts 
                         +44 (0) 1737 821 
 Simon Vane Percy         890 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

UPDCKBDNKBKKCNB

(END) Dow Jones Newswires

March 22, 2019 03:01 ET (07:01 GMT)

1 Year Verseon Chart

1 Year Verseon Chart

1 Month Verseon Chart

1 Month Verseon Chart
Your Recent History
LSE
VERS
Verseon
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20190522 13:33:16